Prothena Corporation PLC
Follow $PRTA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $PRTA by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PRTA moving today?
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PRTA overview
Related filings and maps
Congress activity in PRTA
No receipt-qualified Congressional disclosure is present for PRTA in the cached public ledger.
PRTA contract awards, year to date.
Public federal awards linked to this ticker.
PRTA lobbying filings, year to date.
Registered lobbying filings matched to Prothena Corporation PLC.